Business Context and Reporting Period
Oragenics, Inc. filed a Form 8-K Current Report on November 15, 2013. The filing reports the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the proposed capital raise:
- Shares Offered: 4,400,000 shares of Common Stock.
- Offering Price: $2.50 per share.
- Gross Proceeds: $11.0 million (prior to underwriting discounts and offering expenses).
- Underwriter: Griffin Securities, Inc.
Material Changes
The material change reported is the execution of an Underwriting Agreement on November 15, 2013. This agreement facilitates a takedown from the Company's shelf registration statement on Form S-3 (File No. 333-190609), which became effective on August 26, 2013.
Outlook and Management Commentary
The offering is expected to close on November 20, 2013, subject to customary closing conditions. The agreement includes standard representations, warranties, indemnification obligations, and termination provisions. A press release announcing the pricing was issued on the same date as the filing.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm the closing date of November 20, 2013, and any conditions precedent to closing.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification and termination clauses.
- Check the prospectus supplement dated November 15, 2013, for the intended use of proceeds.